512 results on '"Fischereder, Michael"'
Search Results
2. #2247 Influence of the diagnosis of atopic dermatitis in childhood on the course of kidney function in young adulthood: a single-center study
3. #1303 Hyperkalaemia-related RAASi reduction and estimated number needed to treat to avoid a first hospitalisation by maintaining RAASi
4. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura
5. Sapovirus – An emerging pathogen in renal transplant recipients?
6. Pathologische Urinbefunde - it's a MUST
7. Alternate‐day dosing of caplacizumab for immune‐mediated thrombotic thrombocytopenic purpura
8. The use of extended-release tacrolimus twice a day might be beneficial for selected kidney transplant recipients: a case report.
9. Polyomavirus exerts detrimental effects on renal function in patients after lung transplantation
10. Nierentransplantation (NTX)
11. Chronische Nierenerkrankung
12. Autoren
13. Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults
14. Noninvasive Diagnosis of Acute Rejection in Renal Transplant Patients Using Mass Spectrometric Analysis of Urine Samples: A Multicenter Diagnostic Phase III Trial
15. After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy
16. Patients' and physicians' awareness of clinical symptoms and disease severity in tuberous sclerosis complex.
17. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment
18. Urin-Streifentest
19. Hyperkalzämie: Häufig steckt eine Tumorerkrankung dahinter: Onkologische Zufallsbefunde
20. Symptoms and Occurrence of Hepatitis E in Solid-Organ Recipients: A Single-Center Experience of the Last Five Years: PUB292
21. Five-year follow-up of a phase I trial of donor-derived modified immune cell infusion in kidney transplantation
22. Behandlung des sekundären Hyperparathyreoidismus bei Dialysepatienten und Transplantationserfolg
23. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura
24. Corrigendum: Disqualification of donor and recipient candidates from the living kidney donation program: Experience of a single-center in Germany
25. Individualised immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study): protocol for a multicentre, open-label, phase II, randomised controlled trial
26. Unerwarteter Kreatininanstieg: Was steckt dahinter?
27. Nierenschutz für Ihre Diabetiker
28. Disqualification of Donor and Recipient Candidates From the Living Kidney Donation Program: Experience of a Single-Center in Germany
29. Humoral response after SARS-CoV-2 booster vaccination in haemodialysis patients with and without prior infection
30. MO914: Development of Antibody Response to SARS-COV-2 Vaccines in Haemodialysis Patients
31. Drug-induced CYP-Induction as Therapy for Tacrolimus Intoxication
32. Predisposing Diseases
33. Diminished Short- and Long-Term Antibody Response after SARS-CoV-2 Vaccination in Hemodialysis Patients
34. Immunsuppression und COVID-19
35. Sirolimus in renal transplant recipients with malignancies in Germany
36. Drug-induced CYP-induction as therapy for tacrolimus intoxication
37. Reader Response: Kidney Function, Kidney Function Decline, and the Risk of Dementia in Older Adults
38. Humoral immunity to SARS-CoV-2 vaccination in haemodialysis patients
39. Donor Toll-Like Receptor 4 Contributes to Ischemia and Reperfusion Injury following Human Kidney Transplantation
40. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura
41. Thrombotic microangiopathy following aortic surgery with hypothermic circulatory arrest: a single-centre experience of an underestimated cause of acute renal failure
42. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
43. SDF-1/CXCR4/CXCR7 is pivotal for vascular smooth muscle cell proliferation and chronic allograft vasculopathy
44. Antibody response to mRNA SARS-CoV-2 vaccines in haemodialysis patients
45. Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults
46. Corrigendum to “Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.” Kidney Int. 2020;97:1287–1296
47. Case report: de novo ANCA-associated vasculitis after kidney transplantation treated with rituximab and plasma exchange
48. Nephron-sparing resection of angiomyolipoma after sirolimus pretreatment in patients with tuberous sclerosis
49. Wenn möglich: organerhaltend operieren: Behandlungsoptionen beim Nierenzellkarzinom
50. Pembrolizumab-induced myocarditis in a patient with malignant mesothelioma: plasma exchange as a successful emerging therapy—case report
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.